Phase IIIb study for relapsed/refractory pediatric/young adult acute lymphoblastic leukemia patients to be treated with CTL019.
Phase of Trial: Phase III
Latest Information Update: 23 Nov 2017
At a glance
- Drugs Tisagenlecleucel-T (Primary)
- Indications Acute lymphoblastic leukaemia
- Focus Adverse reactions; Expanded access
- Sponsors Novartis Pharma A.G.
- 10 Mar 2017 New trial record